EGFR inhibition augments the therapeutic efficacy of the NAT10 inhibitor Remodelin in Colorectal cancer.

导出 OA

翻译打印收藏纠错

第一作者： Yongbin,Zheng

第一单位： Department of Gastrointestinal Surgery, Key Laboratory of Hubei Province for Digestive System Disease, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430000, China.

作者： Yongbin,Zheng ^[1] ; Dan,Song ^[1] ; Ming,Guo ^[2] ; Chenhong,Wang ^[1] ; Mingzhen,Ma ^[1] ; Gongcai,Tao ^[1] ; Licui,Liu ^[1] ; Xiaobo,He ^[1] ; Fengyu,Cao ^[1] ; Dan,Luo ^[3] ; Qingchuan,Zhao ^[4] ; Zhongyuan,Xia ^[5] ; Yanxin,An ^[6]

作者单位： Department of Gastrointestinal Surgery, Key Laboratory of Hubei Province for Digestive System Disease, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430000, China. ^[1] Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430000, China. ^[2] Department of Gastroenterology, Minda Hospital of Hubei Minzu University, Enshi, 445000, China. ^[3] State Key Laboratory of Cancer Biology, National Clinical Research Center for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, Shaanxi Province, 710032, China. ^[4] Department of Anesthesiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430000, China. xiazhongyuan2005@aliyun.com. ^[5] Department of General Surgery, The First Affiliated Hospital of Xi 'an Medical University, No. 48 Fenghao West Road, Lianhu District, Xi 'an, Shaanxi Province, 710077, China. anyanxin@xiyi.edu.cn. ^[6]

关键词 Cetuximab Colorectal cancer N-acetyltransferase 10 Remodelin